Gilda’s Club Chicago, cancer organizations launch metastatic breast cancer awareness campaign

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

GILDA’S CLUB CHICAGO and other organizations across the country launched the It’s About Time campaign, an initiative to raise awareness of metastatic breast cancer.

“It is our hope that the It’s About Time campaign will help inform the public about metastatic breast cancer and metastatic disease in general, while giving those diagnosed, their families and friends a greater voice. ” said Laura-Jane Hyde, CEO, Gilda’s Club Chicago said in a statement.

It’s About Time encourages metastatic breast cancer patients, their families, caretakers and advocacy organizations to engage in a national conversation over the next six weeks about metastatic breast cancer facts, what time means to them, opportunities for increased advocacy and research supporting metastatic breast cancer, and, most importantly, to create a platform for those battling metastatic breast cancer to share their stories.

Table of Contents

YOU MAY BE INTERESTED IN

At the Sept. 4 meeting of the National Cancer Advisory Board, NCI Principal Deputy Director Douglas R. Lowy provided an overview of how NCI is weathering the maelstrom of executive orders, policy changes, and funding uncertainties that has come down on federal agencies and research institutes since Donald Trump’s inauguration in January. 
A Senate hearing that the administration hoped would be a routine check-in on the president’s 2026 MAHA-driven healthcare agenda erupted into a political firestorm as senators jumped at their first opportunity to confront HHS Secretary Robert F. Kennedy Jr. over the chaos engulfing the Centers for Disease Control and Prevention.
In December 1971, President Richard Nixon signed the National Cancer Act and declared a “War on Cancer.” In the past 54 years, the U.S. has invested $180 billion nominally, or approximately $322 billion when adjusted for inflation, in cancer research. This investment has paid dividends with more than 100 anticancer drugs brought to market in half a century—virtually all traceable to National Cancer Institute funding. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login